




Biodel Inc. to Present at 28th Annual JPMorgan Healthcare Conference on January 14th, 2010
DANBURY, Conn.--([ BUSINESS WIRE ])--Biodel Inc. (Nasdaq: BIOD) today announced that Dr. Solomon Steiner, Chairman and CEO of Biodel, will present a corporate update at the 28th Annual JPMorgan Healthcare Conference on Thursday, January 14, 2010 at 8:30 a.m. Pacific Time.
The JPMorgan Healthcare Conference will be held January 11-14, 2010, at the Westin St. Francis Hotel in San Francisco, California.
Interested parties may access the presentation in the investor relations section of Biodel's website at [ www.biodel.com ] which will link to a live webcast to be archived for 14 days.
About Biodel Inc.
Biodel is a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for endocrine disorders such as diabetes. Biodel's product candidates are developed using technology which reformulates existing FDA-approved peptide drugs. For further information regarding Biodel, please visit the company's website at [ www.biodel.com ].
BIOD-G